TECH.AX vs. CURE.AX

Last updated Jul 16, 2026

TECH.AX (Global X Morningstar Global Technology ETF) and CURE.AX (Global X S&P Biotech ETF) are both exchange-traded funds - TECH.AX is a Technology Equities fund tracking the Global X Morningstar Global Technology Index, while CURE.AX is a Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index. Both are passively managed. Over the past 5 years, TECH.AX returned 9.17%/yr vs 5.62%/yr for CURE.AX. At a 0.46 correlation, their price movements are largely independent.

Performance

TECH.AX vs. CURE.AX - Performance Comparison

The chart below illustrates the hypothetical performance of a A$10,000 investment in Global X Morningstar Global Technology ETF (TECH.AX) and Global X S&P Biotech ETF (CURE.AX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TECH.AX achieves a 13.34% return, which is significantly lower than CURE.AX's 22.66% return.

TECH.AX

• 1D: -0.93%
• 1M: -1.39%
• 6M: 13.58%
• YTD: 13.34%
• 1Y: 10.92%
• 3Y*: 13.91%
• 5Y*: 9.17%
• 10Y*: —

CURE.AX

• 1D: 0.58%
• 1M: 17.05%
• 6M: 20.39%
• YTD: 22.66%
• 1Y: 65.69%
• 3Y*: 21.60%
• 5Y*: 5.62%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

TECH.AX vs. CURE.AX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
TECH.AX Global X Morningstar Global Technology ETF	13.34%	0.78%	22.63%	38.47%	-29.11%	22.40%	34.82%	39.22%	-3.49%
CURE.AX Global X S&P Biotech ETF	22.66%	25.25%	8.13%	10.63%	-22.98%	-17.10%	38.31%	35.60%	-13.56%

Correlation

The correlation between TECH.AX and CURE.AX is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.26
Correlation (3Y) Calculated over the trailing 3-year period	0.36
Correlation (5Y) Calculated over the trailing 5-year period	0.43
Correlation (All Time) Calculated using the full available price history since Nov 8, 2018	0.46

The correlation between TECH.AX and CURE.AX shifts across timeframes, from 0.26 (1 year) to 0.46 (all time), reflecting how their relationship changes across market environments.

Return for Risk

TECH.AX vs. CURE.AX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TECH.AX

TECH.AX Risk / Return Rank: 18
TECH.AX Sharpe Ratio Rank: 20
TECH.AX Sortino Ratio Rank: 20
TECH.AX Omega Ratio Rank: 20
TECH.AX Calmar Ratio Rank: 15
TECH.AX Martin Ratio Rank: 15

CURE.AX

CURE.AX Risk / Return Rank: 90
CURE.AX Sharpe Ratio Rank: 92
CURE.AX Sortino Ratio Rank: 90
CURE.AX Omega Ratio Rank: 87
CURE.AX Calmar Ratio Rank: 95
CURE.AX Martin Ratio Rank: 87

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TECH.AX vs. CURE.AX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X Morningstar Global Technology ETF (TECH.AX) and Global X S&P Biotech ETF (CURE.AX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	TECH.AX	CURE.AX	Difference
Sharpe ratio: Return per unit of total volatility	0.57	2.62	-2.05
Sortino ratio: Return per unit of downside risk	0.93	3.46	-2.53
Omega ratio: Gain probability vs. loss probability	1.11	1.43	-0.31
Calmar ratio: Return relative to maximum drawdown	0.46	5.80	-5.34
Martin ratio: Return relative to average drawdown	0.99	14.61	-13.62

TECH.AX vs. CURE.AX - Sharpe Ratio Comparison

The current TECH.AX Sharpe Ratio is 0.57, which is lower than the CURE.AX Sharpe Ratio of 2.62. The chart below compares the historical Sharpe Ratios of TECH.AX and CURE.AX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

TECH.AX vs. CURE.AX - Drawdown Comparison

The maximum TECH.AX drawdown since its inception was -31.78%, smaller than the maximum CURE.AX drawdown of -59.81%. Use the drawdown chart below to compare losses from any high point for TECH.AX and CURE.AX.

Drawdown Indicators

	TECH.AX	CURE.AX	Difference
Max Drawdown Largest peak-to-trough decline	-31.78%	-59.81%	+28.03%
Max Drawdown (1Y) Largest decline over 1 year	-26.30%	-11.68%	-14.62%
Max Drawdown (3Y) Largest decline over 3 years	-26.49%	-28.37%	+1.88%
Max Drawdown (5Y) Largest decline over 5 years	-31.78%	-50.92%	+19.14%
Current Drawdown Current decline from peak	-6.24%	-5.45%	-0.79%
Average Drawdown Average peak-to-trough decline	-7.73%	-27.38%	+19.65%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.27%	4.66%	+7.61%

Volatility

TECH.AX vs. CURE.AX - Volatility Comparison

The current volatility for Global X Morningstar Global Technology ETF (TECH.AX) is 6.78%, while Global X S&P Biotech ETF (CURE.AX) has a volatility of 9.67%. This indicates that TECH.AX experiences smaller price fluctuations and is considered to be less risky than CURE.AX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TECH.AX	CURE.AX	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.78%	9.67%	-2.89%
Volatility (6M) Calculated over the trailing 6-month period	18.70%	21.01%	-2.31%
Volatility (1Y) Calculated over the trailing 1-year period	21.13%	25.95%	-4.82%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	21.61%	30.91%	-9.30%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	21.03%	31.70%	-10.67%

Dividends

TECH.AX vs. CURE.AX - Dividend Comparison

TECH.AX's dividend yield for the trailing twelve months is around 3.40%, while CURE.AX has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
CURE.AX Global X S&P Biotech ETF	0.00%	0.00%	0.00%	0.00%	0.06%	11.64%	9.47%	2.05%	0.00%	0.00%
TECH.AX Global X Morningstar Global Technology ETF	3.40%	11.08%	6.23%	0.50%	4.95%	13.65%	7.67%	7.75%	6.07%	0.84%

Frequently Asked Questions

Can I hold both TECH.AX and CURE.AX in my portfolio?

TECH.AX and CURE.AX have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

What is the main difference between TECH.AX and CURE.AX?

TECH.AX is categorized as Technology Equities, while CURE.AX is Health & Biotech Equities. TECH.AX tracks Global X Morningstar Global Technology Index, while CURE.AX tracks S&P Biotechnology Select Industry Index.